SABS FY2030 EPS Boosted by Brookline Capital Markets

Key Points

• Brookline Capital Markets raised SAB Biotherapeutics’ FY2030 EPS forecast to $1.38 from $1.17, while the current full-year consensus remains a loss of $1.19 per share.
• SAB Biotherapeutics reported quarterly EPS of -$0.28, matching analysts’ expectations.
• Analyst sentiment is broadly positive, with a consensus “Moderate Buy” rating and a $12.00 target price; however, the stock recently opened at $3.85 and has a negative trailing P/E ratio.

SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) - Analysts at Brookline Capital Markets upped their FY2030 earnings estimates for shares of SAB Biotherapeutics in a research note issued on Thursday, August 6th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings of $1.38 per share for the year, up from their previous forecast of $1.17. The consensus estimate for SAB Biotherapeutics' current full-year earnings is ($1.19) per share.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28).

Other analysts have also recently issued research reports about the company. Leerink Partners lifted their price target on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, June 15th. Wall Street Zen lowered SAB Biotherapeutics from a "sell" rating to a "strong sell" rating in a report on Sunday, August 2nd. Zacks Research raised SAB Biotherapeutics from a "strong sell" rating to a "hold" rating in a report on Monday, May 11th. Chardan Capital raised their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a "buy" rating in a research note on Wednesday, June 17th. Finally, Barclays started coverage on SAB Biotherapeutics in a report on Wednesday, June 24th. They set an "overweight" rating and a $13.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, SAB Biotherapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $12.00.

SAB Biotherapeutics Price Performance

Shares of SABS opened at $3.85 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The company's fifty day moving average price is $3.68 and its 200-day moving average price is $3.83. SAB Biotherapeutics has a 1-year low of $1.85 and a 1-year high of $5.15. The firm has a market capitalization of $294.37 million, a PE ratio of -1.82 and a beta of 0.53.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. acquired a new stake in SAB Biotherapeutics during the 1st quarter worth about $29,000. ADAR1 Capital Management LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the third quarter worth about $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter worth about $34,000. Finally, Virtu Financial LLC acquired a new stake in SAB Biotherapeutics during the third quarter worth about $40,000. 7.82% of the stock is owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source